<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797849</url>
  </required_header>
  <id_info>
    <org_study_id>#871</org_study_id>
    <secondary_id>Contract 1 EA-0000078</secondary_id>
    <secondary_id>Subaward for W81XWH-06-1-0279</secondary_id>
    <nct_id>NCT00797849</nct_id>
  </id_info>
  <brief_title>Controlled Study of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees</brief_title>
  <official_title>A Randomized, Controlled Study to Evaluate the Effectiveness of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samueli Institute for Information Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if the group using Farabloc shows a greater
      reduction in pain levels than the group not using Farabloc at 6-week, 12-week and 1-month
      post treatment follow-ups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phantom limb pain (PLP)is a painful sensation perceived in the missing limb after amputation
      and may be triggered by episodes of stump pain. A growing body of literature indicates that
      50-80% of amputees may have PLP. Farabloc cloth is a noninvasive, alternative therapy
      developed by Farabloc Development Corporation for use by amputees with PLP. The Farabloc
      Corporation will be donating them to the VA Long Beach for use in this study without charge.
      Farabloc is a non-toxic and non-invasive treatment with promising preliminary pilot data.
      Metallic fibers consisting mainly of iron (85.3%) and nickel (10.0%) are woven into a nylon
      fabric that can be custom made into socks, gloves, limb covers, etc. Farabloc can be
      laminated into the socket and in the design of the prosthetic without weakening or adding
      significant weight to it. The exact mechanism of action is unknown for Farabloc, however, it
      is theorized that the fabric shields high frequency electromagnetic fields that may cause
      cellular damage and subsequent pain.

      Subjects over 18 will be recruited from the VA Long Beach Prosthetic Clinic. Eligible
      subjects who are interested to participate, will be scheduled for a screening visit. Written
      informed consent will be obtained before enrollment. Enrolled subjects will be randomly
      assigned to either the Farabloc or sham Farabloc group. Assignment is double-blind to study
      participants, prosthetist, Farabloc Corporation and the research assistant throughout the
      study. Only the project coordinator and PI will know the random assignment.

      Farabloc intervention will consist of wearing prosthetics laminated with Farabloc surrounding
      the liner or, if not wearing prosthetics, subject will wear Farabloc sock or glove over
      shrinker. Sham intervention will consist of wearing prosthetics laminated with sham fabric
      surrounding the liner or, if not wearing prosthetics, subject will wear sock or glove made of
      sham fabric over shrinker. All subjects will receive at least two socks.

      Data for PLP pain levels and health-related quality of life will be collected during
      baseline, 6-week, 12-week and 1-month post treatment follow-up. Research staff will
      administer these surveys and collect data in person. The amount of health care utilization
      will be measured 12-week prior ot enrollment and 12-week follow-up. Monitoring adherence to
      protocol by phone call will be made during the treatment at 3-week and 9-week followup.

      Study participants will receive a total of $50 for their participation in this study ($20 for
      baseline and $10 for each of the three follow-up visits). At the end of the study,
      participants can choose to keep the active or sham Farabloc. If the true Farabloc turns out
      to be an effective treatment for phantom limb pain, subjects assigned to the sham Farabloc
      intervention will b offered the option to be treated with true Farabloc free of charge aftr
      conclusion of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be pain as measured by the Numerical Pain Rating Scale (NPRS).</measure>
    <time_frame>Measurements will be obtained at baseline, and 6-week and 12-week follow-ups</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary outcome will measure health-related quality of life using the 36-item Sort Form Health Survey (SF-36).</measure>
    <time_frame>The assessment will be conducted at pretest, 6-week, 12-week and 1-month post treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of health care utilization will be conducted by comparing the numbers of outpatient visits emergency room visits and inpatient hospitalizations using the VA electronic medical system CPRS.</measure>
    <time_frame>At 12-week pretreatment and 12-week follow-up.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Phantom Limb Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Farabloc Limb Cover</intervention_name>
    <description>Wear prosthetics, sock or glove laminated with Farabloc</description>
    <arm_group_label>1</arm_group_label>
    <other_name>FARABLOC - LC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Limb Cover</intervention_name>
    <description>Wear prosthetics, sock or glove laminated with sham material</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upper or lower extremity amputees with healed stumps

          -  Experience episodes or intermittent PLP

          -  At least 3 episodes of PLP during the previous 6 weeks

          -  Have not used Farabloc within the last 6 months

        Exclusion Criteria:

          -  Pregnant women are excluded from the study

          -  Stump complications (e.g., cellulites and stump pain caused by new bone spur within
             the past 12 months

          -  Previous use of Farabloc within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>An-Fu Hsiao, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Long Beach Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822-5201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.scire-lb.org/</url>
    <description>Southern California Institute for Research and Education Website</description>
  </link>
  <reference>
    <citation>Adams PF, Hendershot GE, Marano MA; Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10. 1999 Oct;(200):1-203.</citation>
    <PMID>15782448</PMID>
  </reference>
  <reference>
    <citation>Ephraim PL, Dillingham TR, Sector M, Pezzin LE, Mackenzie EJ. Epidemiology of limb loss and congenital limb deficiency: a review of the literature. Arch Phys Med Rehabil. 2003 May;84(5):747-61. Review.</citation>
    <PMID>12736892</PMID>
  </reference>
  <reference>
    <citation>Potter BK, Scoville CR. Amputation is not isolated: an overview of the US Army Amputee Patient Care Program and associated amputee injuries. J Am Acad Orthop Surg. 2006;14(10 Spec No.):S188-90. Review.</citation>
    <PMID>17003197</PMID>
  </reference>
  <reference>
    <citation>Lin DL, Kirk KL, Murphy KP, McHale KA, Doukas WC. Evaluation of orthopaedic injuries in Operation Enduring Freedom. J Orthop Trauma. 2004 May-Jun;18(5):300-5.</citation>
    <PMID>15105752</PMID>
  </reference>
  <reference>
    <citation>Islinger RB, Kuklo TR, McHale KA. A review of orthopedic injuries in three recent U.S. military conflicts. Mil Med. 2000 Jun;165(6):463-5.</citation>
    <PMID>10870364</PMID>
  </reference>
  <reference>
    <citation>Korver AJ. Amputees in a hospital of the International Committee of the Red Cross. Injury. 1993 Oct;24(9):607-9.</citation>
    <PMID>8288381</PMID>
  </reference>
  <reference>
    <citation>Sherman RA. Phantom limb pain. Mechanism-based management. Clin Podiatr Med Surg. 1994 Jan;11(1):85-106. Review.</citation>
    <PMID>8124659</PMID>
  </reference>
  <reference>
    <citation>Ephraim PL, Wegener ST, MacKenzie EJ, Dillingham TR, Pezzin LE. Phantom pain, residual limb pain, and back pain in amputees: results of a national survey. Arch Phys Med Rehabil. 2005 Oct;86(10):1910-9.</citation>
    <PMID>16213230</PMID>
  </reference>
  <reference>
    <citation>Kooijman CM, Dijkstra PU, Geertzen JH, Elzinga A, van der Schans CP. Phantom pain and phantom sensations in upper limb amputees: an epidemiological study. Pain. 2000 Jul;87(1):33-41.</citation>
    <PMID>10863043</PMID>
  </reference>
  <reference>
    <citation>Dijkstra PU, Geertzen JH, Stewart R, van der Schans CP. Phantom pain and risk factors: a multivariate analysis. J Pain Symptom Manage. 2002 Dec;24(6):578-85.</citation>
    <PMID>12551807</PMID>
  </reference>
  <reference>
    <citation>Richardson C, Glenn S, Nurmikko T, Horgan M. Incidence of phantom phenomena including phantom limb pain 6 months after major lower limb amputation in patients with peripheral vascular disease. Clin J Pain. 2006 May;22(4):353-8.</citation>
    <PMID>16691088</PMID>
  </reference>
  <reference>
    <citation>Whyte A, Niven CA. The illusive phantom: does primary care meet patient need following limb loss? Disabil Rehabil. 2004 Jul 22-Aug 5;26(14-15):894-900.</citation>
    <PMID>15497918</PMID>
  </reference>
  <reference>
    <citation>Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. Pain. 1984 Jan;18(1):83-95.</citation>
    <PMID>6709380</PMID>
  </reference>
  <reference>
    <citation>Wartan SW, Hamann W, Wedley JR, McColl I. Phantom pain and sensation among British veteran amputees. Br J Anaesth. 1997 Jun;78(6):652-9.</citation>
    <PMID>9215014</PMID>
  </reference>
  <reference>
    <citation>Amir R, Devor M. Ongoing activity in neuroma afferents bearing retrograde sprouts. Brain Res. 1993 Dec 10;630(1-2):283-8.</citation>
    <PMID>8118694</PMID>
  </reference>
  <reference>
    <citation>Jain N, Florence SL, Kaas JH. Reorganization of Somatosensory Cortex After Nerve and Spinal Cord Injury. News Physiol Sci. 1998 Jun;13:143-149.</citation>
    <PMID>11390778</PMID>
  </reference>
  <reference>
    <citation>Flor H, Elbert T, MÃ¼hlnickel W, Pantev C, Wienbruch C, Taub E. Cortical reorganization and phantom phenomena in congenital and traumatic upper-extremity amputees. Exp Brain Res. 1998 Mar;119(2):205-12.</citation>
    <PMID>9535570</PMID>
  </reference>
  <reference>
    <citation>Chabal C, Jacobson L, Russell LC, Burchiel KJ. Pain responses to perineuromal injection of normal saline, gallamine, and lidocaine in humans. Pain. 1989 Mar;36(3):321-5.</citation>
    <PMID>2710561</PMID>
  </reference>
  <reference>
    <citation>Parkes CM. Factors determining the persistence of phantom pain in the amputee. J Psychosom Res. 1973 Mar;17(2):97-108.</citation>
    <PMID>4741689</PMID>
  </reference>
  <reference>
    <citation>Shukla GD, Sahu SC, Tripathi RP, Gupta DK. Phantom limb: a phenomenological study. Br J Psychiatry. 1982 Jul;141:54-8.</citation>
    <PMID>7116073</PMID>
  </reference>
  <reference>
    <citation>Jensen MP, Turner JA, Romano JM. What is the maximum number of levels needed in pain intensity measurement? Pain. 1994 Sep;58(3):387-92.</citation>
    <PMID>7838588</PMID>
  </reference>
  <reference>
    <citation>Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and validity of chronic pain intensity measures. Pain. 1999 Nov;83(2):157-62.</citation>
    <PMID>10534586</PMID>
  </reference>
  <reference>
    <citation>McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994 Jan;32(1):40-66.</citation>
    <PMID>8277801</PMID>
  </reference>
  <reference>
    <citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.</citation>
    <PMID>1593914</PMID>
  </reference>
  <reference>
    <citation>Kazis LE, Ren XS, Lee A, Skinner K, Rogers W, Clark J, Miller DR. Health status in VA patients: results from the Veterans Health Study. Am J Med Qual. 1999 Jan-Feb;14(1):28-38.</citation>
    <PMID>10446661</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <name_title>An-Fu Hsiao, M.D., Ph.D.</name_title>
    <organization>Southern California Institute for Research and Education</organization>
  </responsible_party>
  <keyword>phantom limb pain</keyword>
  <keyword>amputees</keyword>
  <keyword>Farabloc</keyword>
  <keyword>Phantom limb pain in the missing limb of Veteran amputees</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phantom Limb</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

